This phase 3 trial randomised 1,144 men with PSMA-positive metastatic hormone-sensitive prostate cancer to standard androgen deprivation plus an androgen-receptor pathway inhibitor, with or without 177Lu-PSMA-617. Two-thirds had high-volume disease. It tests whether a radioligand therapy used late, in castration-resistant disease, earns its place earlier.
Adding 177Lu-PSMA-617 improved radiographic progression-free survival, cutting the risk of radiographic progression or death by 28% (hazard ratio 0.72, 95% CI 0.58 to 0.90; p=0.0021). Grade 3 or worse adverse events were more frequent (51% versus 43%), and dry mouth affected 46% versus 4%, though these were grade 1–2; cytopenias and gastrointestinal effects were also more common. There were no unexpected safety signals.
This is a genuine expansion of who radioligand therapy is for. Overall survival is not yet mature, so the case rests on delayed progression and a manageable toxicity trade-off. Where PSMA PET and 177Lu-PSMA-617 are available, this becomes a real option to discuss up front in metastatic hormone-sensitive disease.
- Population: PSMA-positive metastatic hormone-sensitive prostate cancer, added to ADT plus an ARPI
- 28% relative reduction in radiographic progression or death (HR 0.72)
- More grade 3+ adverse events (51% vs 43%); dry mouth in 46%, mostly mild
- Overall survival immature — counsel on delayed progression, not yet a survival claim
The statistics, in plain English
A hazard ratio of 0.72 for radiographic progression-free survival means that at any point, patients on 177Lu-PSMA-617 had 72% of the progression-or-death risk of controls — a 28% relative reduction; the interval (0.58 to 0.90) sits below 1.0, so it is statistically robust. Because median follow-up is short and overall survival not yet reported, this is a progression benefit, not yet proof of longer life.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free